In Ontario, the heterozygote (medium activity) [OR: 1.66, 95%CI (1.18–2.33)] and high activity [OR: 2.22, 95%CI (1.49–3.28)] combinations of CCND1 and COMT genotypes showed statistically significant association with increased breast cancer risk. The gene discussed is CCND1; the disease is breast carcinoma.